At Aegros we believe access to life saving therapeutic plasma drugs is a human right and not a privilege. Our mission is to put the patient first through innovation and we do thanks to the Australian invented HaemaFrac®, Aegros' unique electroseparation process. Our TGA GMP-approved plasma fractionation plant in Macquarie Park, Sydney, manufactures a hyperimmune immunoglobulin product against Covid-19, made from convalescent plasma. Aegros is currently undertaking the final precommercial phase of a clinical trial of our Covid-19 hyperimmune in conjunction with a major Sydney hospital.